<DOC>
	<DOCNO>NCT00078819</DOCNO>
	<brief_summary>This study evaluate safety efficacy etanercept ( Enbrel® ) child Psoriasis . This Phase 3 blind , placebo-controlled study .</brief_summary>
	<brief_title>Etanercept ( Enbrel® ) Psoriasis - Pediatrics</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients plaque psoriasis Patient may receive certain psoriasis medication study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pediatric Psoriasis</keyword>
</DOC>